Volume 35 Number 8S II (liraglutide, saxagliptin), depression (agomelatine), bipolar disorder (asenapine), and epilepsy (eslicarbazepine). Data of all Phase II and III trials were identified in the European public assessment reports, the WHO Trials Registry, and PubMed. Outcome measures: the number of randomized subjects and the number of those aged 65 and 75 years and older. Trials with missing data were not included in the calculation of that outcome. Rates of trials giving information about the number of older subjects and the proportions of older people were calculated.
OC019-INTrapulmONary pharmaCOkINeTICS (pk) aNd The INTraCellular dISpOSITION TO SuppOrT The lONg-laSTINg effICaCy afTer aN INhaled admINISTraTION Of ITS prOdrug laNINamIVIr OCTaNOaTe (lO)
Osaka Pharmacology Clinical Research Hospital, Osaka, Japan Introduction: A single inhaled dose of laninamivir octanoate (LO), a long-acting neuraminidase inhibitor, exhibits efficacy to treat both adult and pediatric patients with influenza virus infection. However, the relation between the intrapulmonary pharmacokinetics (PK) of LO and laninamivir, an active metabolite, and its long-lasting efficacy has not fully been investigated. Intrapulmonary pharmacokinetics in healthy volunteers and the intracellular drug disposition in mice were evaluated to clarify the potential mechanism for the prolonged high intrapulmonary retention of laninamivir, which would support its long-lasting efficacy. Patients (or Materials) and Methods: A single-center, open-label study was performed in adult healthy volunteers. Seven subgroups of 5 subjects each underwent bronchoalveolar lavage (BAL) at specified time intervals from 4 to 240 hours after a single inhaled administration of LO (40 mg). Plasma, BAL fluid, and alveolar macrophage (AM) were analyzed to determine laninamivir and LO concentrations using validated LC-MS/MS methods. The concentrations in epithelial lining fluid (ELF) were calculated by the urea diffusion method. Microautoradiographic localization in the respiratory tissues was evaluated after a single intranasal administration of radiolabeled LO to mice. In addition, the disposition of LO and laninamivir was evaluated by measuring the drug uptake and release in primary cultured mouse airway epithelial cells. Results: In healthy volunteers, the peak plasma concentrations of laninamivir occurred at 3.5 hours after inhalation and decreased with the half-life of 45.7 hours. Laninamivir concentrations in ELF and AM were much higher than those in plasma and lasted for 240 hours. C max of laninamivir in ELF from first BAL was 8.6 μ g/mL and laninamivir in ELF decreased with longer half-life (~6 days) than that in plasma. Laninamivir concentrations in ELF notably exceeded the IC50 values for viral neuraminidase at all time points examined. In mice, the labeled LO derived activity after an intranasal administration mainly located on the epithelial cells for a long period. The uptake of LO in airway epithelial cells increased without any apparent saturation even at the highest concentration tested (1000 μ M). Furthermore, the intracellular laninamivir was released very slowly into the drug-free medium, which was regarded as a rate-limiting step in the cellular retention. Conclusion: ELF concentration profiles and prolonged high intrapulmonary retention of laninamivir support its long-lasting efficacy to treat patients with influenza virus infection by the single inhalation. Paulo, Ribeirão Preto, Brazil; and 4 Leiden University, Leiden, the Netherlands Introduction: Busulfan, an alkylating agent, is used in combination with other drugs in patients undergoing stem cell transplantation. Busulfan presents a very narrow therapeutic window, which has been linked to various adverse events. Therapeutic monitoring protocols have been developed to allow the individualization of the dose, but the dose selection and the sampling time for pharmacokinetics are based on empirical evidence. Consequently, target exposure cannot be warranted. The aim of this investigation was to determine the optimal sampling scheme and develop a model-based dosing algorithm for busulfan in stem cell transplantation patients. Patients (or Materials) and Methods: Clinical data (n = 29) from an ongoing study were used for the purposes our analysis. A 1-compartment model was selected as basis for sampling optimization and subsequent evaluation of a suitable dosing algorithm. Internal and external model validation procedures were performed before the optimization steps using ED-optimality criteria. Clearance and volume of distribution were considered as parameters of interest. The final sampling scheme and dosing algorithm were based on the deviation from target exposure range, as determined by AUC (0) (1) (2) (3) (4) (5) (6) . Results: A 1-compartment model was found to describe busulfan exposure after oral administration, with ideal body weight (IBW) and alanine transferase (ALT) as covariates on clearance. A sparse sampling scheme with five samples per patient (t = 0.5, 2.25, 3, 4, and 5 hours after dose) was found to be sufficient for the characterization
